Flutamide (FLU) is a non-steroidal antiandrogen drug approved for the treatment of advanced prostate cancer. While this indication limits the use to male patients, FLU is widely prescribed to women, off-label, for the treatment of polycystic ovary syndrome (POCS) related hirsutism and acne. According to the literature, its assumption is associated with a higher incidence of adverse events in women than in male patients.
Giorgetti, R., di Muzio, M., Giorgetti, A., Girolami, D., Borgia, L., Tagliabracci, A. (2017). Flutamide-induced hepatotoxicity: ethical and scientific issues. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 21(1 Suppl), 69-77.
Flutamide-induced hepatotoxicity: ethical and scientific issues
Giorgetti, A;
2017
Abstract
Flutamide (FLU) is a non-steroidal antiandrogen drug approved for the treatment of advanced prostate cancer. While this indication limits the use to male patients, FLU is widely prescribed to women, off-label, for the treatment of polycystic ovary syndrome (POCS) related hirsutism and acne. According to the literature, its assumption is associated with a higher incidence of adverse events in women than in male patients.| File | Dimensione | Formato | |
|---|---|---|---|
|
69-77-Flutamide-induced-hepatotoxicity.pdf
accesso aperto
Tipo:
Versione (PDF) editoriale / Version Of Record
Licenza:
Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale - Non opere derivate (CCBYNCND)
Dimensione
434.86 kB
Formato
Adobe PDF
|
434.86 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
